These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
206 related articles for article (PubMed ID: 29796823)
41. Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS). Sinclair A; Appel G; Dooley MA; Ginzler E; Isenberg D; Jayne D; Wofsy D; Solomons N Lupus; 2007; 16(12):972-80. PubMed ID: 18042591 [TBL] [Abstract][Full Text] [Related]
42. Mycophenolate mofetil versus azathioprine as maintenance therapy for lupus nephritis: a meta-analysis. Feng L; Deng J; Huo DM; Wu QY; Liao YH Nephrology (Carlton); 2013 Feb; 18(2):104-10. PubMed ID: 23113811 [TBL] [Abstract][Full Text] [Related]
43. Immunosuppressive treatment for pure membranous lupus nephropathy in a Hispanic population. Mejía-Vilet JM; Córdova-Sánchez BM; Uribe-Uribe NO; Correa-Rotter R Clin Rheumatol; 2016 Sep; 35(9):2219-27. PubMed ID: 27475791 [TBL] [Abstract][Full Text] [Related]
44. Pilot study comparing the childhood arthritis and rheumatology research alliance consensus treatment plans for induction therapy of juvenile proliferative lupus nephritis. Cooper JC; Rouster-Stevens K; Wright TB; Hsu JJ; Klein-Gitelman MS; Ardoin SP; Schanberg LE; Brunner HI; Eberhard BA; Wagner-Weiner L; Mehta J; Haines K; McCurdy DK; Phillips TA; Huang Z; von Scheven E; Pediatr Rheumatol Online J; 2018 Oct; 16(1):65. PubMed ID: 30348175 [TBL] [Abstract][Full Text] [Related]
45. Mycophenolate mofetil in the treatment of systemic lupus erythematosus. Dall'Era M Curr Opin Rheumatol; 2011 Sep; 23(5):454-8. PubMed ID: 21720247 [TBL] [Abstract][Full Text] [Related]
46. [Mycophenolate mofetil for the treatment of lupus nephritis. The case of lupus nephritis--class IV according to WHO--treated with mycophenolate mofetil]. Suszek D; Wielosz E; Majdan M Ann Acad Med Stetin; 2010; 56 Suppl 1():91-4. PubMed ID: 21365951 [TBL] [Abstract][Full Text] [Related]
47. Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Radhakrishnan J; Moutzouris DA; Ginzler EM; Solomons N; Siempos II; Appel GB Kidney Int; 2010 Jan; 77(2):152-60. PubMed ID: 19890271 [TBL] [Abstract][Full Text] [Related]
48. Management practice and treatment outcomes of adult patients with Lupus Nephritis at the Renal Clinic of St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia. Hailu GT; Hussen SU; Getachew S; Berha AB BMC Nephrol; 2022 Jun; 23(1):214. PubMed ID: 35715762 [TBL] [Abstract][Full Text] [Related]
49. Mycophenolate mofetil for lupus nephritis: an update. Mok CC Expert Rev Clin Immunol; 2015; 11(12):1353-64. PubMed ID: 26364748 [TBL] [Abstract][Full Text] [Related]
50. The efficacy of induction treatment in Thai patients with lupus nephritis: Observational cohort analysis. Pichaiwong W; Lawanaskol S; Phinyo P; Kitumnuaypong T Lupus; 2023 Mar; 32(3):444-452. PubMed ID: 36602394 [TBL] [Abstract][Full Text] [Related]
51. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials. Zhu B; Chen N; Lin Y; Ren H; Zhang W; Wang W; Pan X; Yu H Nephrol Dial Transplant; 2007 Jul; 22(7):1933-42. PubMed ID: 17405792 [TBL] [Abstract][Full Text] [Related]
52. Can we identify who gets benefit or harm from mycophenolate mofetil in systemic lupus erythematosus? A systematic review. Mendoza-Pinto C; Pirone C; van der Windt DA; Parker B; Bruce IN Semin Arthritis Rheum; 2017 Aug; 47(1):65-78. PubMed ID: 28325471 [TBL] [Abstract][Full Text] [Related]
54. The Effect of Mycophenolate Mofetil as First-Line Therapy on the Timing of Urine Protein-to-Creatinine Ratio Reduction in Immunosuppressant-Naive Patients With Lupus Nephritis at a Single Center. Timlin H; Hardenbergh D; Fine D; Monroy-Trujillo JM; Haque U; Adler B; Vaidya D; Geetha D J Clin Rheumatol; 2022 Jan; 28(1):e141-e144. PubMed ID: 33394827 [TBL] [Abstract][Full Text] [Related]
55. Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study. Moroni G; Raffiotta F; Trezzi B; Giglio E; Mezzina N; Del Papa N; Meroni P; Messa P; Sinico AR Rheumatology (Oxford); 2014 Sep; 53(9):1570-7. PubMed ID: 24505125 [TBL] [Abstract][Full Text] [Related]
56. Mycophenolate Mofetil in Nonrenal Manifestations of Systemic Lupus Erythematosus: An Observational Cohort Study. Tselios K; Gladman DD; Su J; Urowitz MB J Rheumatol; 2016 Mar; 43(3):552-8. PubMed ID: 26773121 [TBL] [Abstract][Full Text] [Related]
57. The effects of cyclophosphamide and mycophenolate on end-stage renal disease and death of lupus nephritis. Koo HS; Kim YC; Lee SW; Kim DK; Oh KH; Joo KW; Kim YS; Ahn C; Han JS; Kim S; Chin HJ Lupus; 2011 Nov; 20(13):1442-9. PubMed ID: 21951944 [TBL] [Abstract][Full Text] [Related]
58. Pro: The use of calcineurin inhibitors in the treatment of lupus nephritis. Mok CC Nephrol Dial Transplant; 2016 Oct; 31(10):1561-6. PubMed ID: 27591327 [TBL] [Abstract][Full Text] [Related]
59. Low risk of renal flares and negative outcomes in women with lupus nephritis conceiving after switching from mycophenolate mofetil to azathioprine. Fischer-Betz R; Specker C; Brinks R; Aringer M; Schneider M Rheumatology (Oxford); 2013 Jun; 52(6):1070-6. PubMed ID: 23382355 [TBL] [Abstract][Full Text] [Related]